Rachel Sachs, JD, MPH, is an Associate Professor of Law at Washington University in St. Louis, where her work explores the interaction of intellectual property law, food and drug regulation, and health law. Professor Sachs’ scholarship has appeared in legal journals that include the Harvard Journal of Law & Technology, the University of California-Davis Law Review, the Yale Journal of Law & Technology, and the peer-reviewed Journal of Law and the Biosciences, and medical journals that include the New England Journal of Medicine and the Annals of Internal Medicine.


Prior to joining the Washington University faculty, Professor Sachs was an Academic Fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics and a Lecturer in Law at Harvard Law School. She also clerked for the Hon. Richard A. Posner of the U.S. Court of Appeals for the Seventh Circuit.


Sachs received her J.D. magna cum laude from Harvard Law School and a Master of Public Health from the Harvard School of Public Health. She received her A.B. in Bioethics from Princeton University.


Recent Posts by Rachel Sachs

FDA User Fee Reauthorization Poised To Pass House of Representatives

On Monday, the House of Representatives released the latest version of the proposed Food and Drug Administration user fee reauthorization bill. The House is expected to vote on the must-pass bill as early as today, but the Senate has not yet set forth its own timeline for voting on the bill.

July 12, 2017Drugs and Medical Innovation

At Drug Hearing, Senators Discuss Meanings Of Price And Value—And Debate Health Reform

On Tuesday, June 13, the Senate HELP Committee held the first of three planned hearings on high drug prices. One of the most important points to come out of the hearing was that there is bipartisan concern about high drug prices, even if there is as yet little agreement on what to do about them.

FDA User Fee Reauthorization Clears Hurdle In Senate With Bipartisan Support

On May 11, the Senate Committee on Health, Education, Labor and Pensions marked up the proposed FDA user fee reauthorization bill and voted 21-2 to advance it to the full Senate. The bill would reauthorize the fee system for FDA approval of drugs, medical devices, generic drugs, and biosimilars.

Value-Based Pricing For Pharmaceuticals In The Trump Administration

A bipartisan consensus has emerged that something must be done to tackle drug prices. There’s less consensus about what that something ought to be. One alternative, “value-based pricing,” may hold promise.

Scott Gottlieb’s FDA Commissioner Confirmation Hearing: Remarkably Unremarkable

In a presidential administration whose confirmation hearings have sparked more than a few contentious moments, FDA Commissioner-designate Scott Gottlieb’s confirmation hearing was remarkable for how unremarkable it was. But to say the hearing was uneventful is not to say that it was uninteresting.

April 7, 2017Drugs and Medical Innovation

Medicaid Expansion Through Section 1115 Waivers: Evaluating The Tradeoffs

A Symposium On Health Law. Just 32 states including DC have expanded Medicaid pursuant to the ACA. Some have successfully negotiated customized expansions with CMS through Section 1115 waivers, seeking to expand Medicaid only on their terms. However, this new set of waivers should give us pause.

The ACA Survives — But With A Note Of Caution For The Future?

Chief Justice Roberts offered two reasons for declining to defer to the IRS’ interpretation of the ACA. But I want to focus on what these two aspects of the Chief Justice’s logic may mean for health law in particular.

The Complex Effects Of The FDA’s Proposal To Regulate Laboratory-Developed Tests

Editor’s note: This post is part of a series stemming from the Third Annual Health Law Year in P/Review event held at Harvard Law School on Friday, January 30, 2015. The conference brought together leading experts to review major developments in health law over the previous year, and preview...

April 10, 2015Drugs and Medical Technology